PATENT ABSTRACTS 321

The present invention relates to novel chem- ically synthesized nucleotides and novel chem- ically synthesized peptides which have been found to be effective in assaying for the presence of M. tuberculosis.

5171840

R E C E P T O R P R O T E I N F O R H U M A N B C E L L S T I M U L A T O R Y

F A C T O R - 2

The preparation and use of polynucleotides and polypeptides corresponding to a novel gene ex- pressed in fetal intestinal endoderm cells and the corresponding gene product, respectively, are disclosed. Expression of the gene, designated the intestinal oncofetal gene, is associated with neoplastic transformation in non-fetal intestinal cells other than adult crypt cells. Clone OCI-5 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rocksville, Maryland 20852, U.S.A., on Aug. 18, 1988, and granted accession No. 40481.

Tadamitsu Kishimoto, Tondabayashi shi, Osaka, Japan

An isolated receptor protein for human B cell stimulatory factor-2, capable of specifically bi- nding to the human B cell stimulatory factor-2; DNA coding for the above-mentioned receptor protein; expression vectors containing the above-mentioned DNA; host organisms trans- formed with the above-mentioned expression vector; a process for production of the receptor protein comprising culturing the host organisms in a medium to produce the receptor protein and recovering the receptor protein from the culture; and a antibody reacting with the protein.

5171843

I M M U N O G E N I C P O L Y P E P T I D E A N D M E T H O D F O R P U R I F Y I N G

I T

Victor Nussenzweig assigned to New York University

This invention relates to a synthetic polypeptide (preferably produced by recombinant DNA techniques) comprising an amino acid sequence incorporating (a) a portion of the P.vivax cir- cumsporozoite (CS) protein including the region of the repeat immunodominant epitope of said protein and (b) another portion of such protein which is conserved among the different material species; and to a method for purifying such a polypeptide.

5173187

M E T H O D F O R C O N T R O L A N D M O N I T O R I N G O F A C T I V A T E D

S L U D G E I N A B I O L O G I C A L C L A R I F I C A T I O N S Y S T E M

Werne Nader, Carl Nebe, Gerhar Nebe, Christia Birr, Heidelberg, Federal Republic Of Germany assigned to Orpegen Medizinisch Molekular- biologische Forschungsgesellschaft m b H

The present invention provides a process for the control of a biological clarification stage of the aerobic activated sludge type, wherein at least one of the micro-organisms most frequently pre- sent in the activated sludge is continuously monitored with regard to the amount thereof in that, in a representative sample from the ac- tivated sludge and/or from the inlet of the ac- tivated sludge tank, this micro-organism is bound to fluorescence-labelled antibodies direc- ted against the chosen micro-organism or this micro-organism is allowed to react with a fluorogenic substrate by means of a special meta- bolic ability, the amount of the thus fluorescence-labelled micro-organism is deter- mined by flow cytometry and, at the same time, the total amount of the micro-organism present is determined by scattered light measurement and/or coloration of the DNA and, depending upon the measurement values thus obtained, the amount of at least one particular micro- organism and/or the growth conditions for this micro-organism is regulated.

5173294

5171850

I N T E S T I N A L O N C O F E T A L G E N E

Jorge Filmus, Ronald Buick, Toronto, Canada assigned to The Ontario Cancer Institute

D N A P R O B E F O R T H E I D E N T I F I C A T I O N O F

H A E M O P H I L U S I N F L U E N Z A E

Timothy F Murphy, Michael A Apicella as- signed to Research Foundation of State Univer- sity of New York